心脏手术中细胞因子清除(RECCAS):一项随机对照试验
RECCAS是一项前瞻性随机对照试验,纳入38例>65岁择期体外循环心脏手术患者,随机分为术中血液吸附(CytoSorb)组(n=19)或标准治疗组(n=19)。主要终点ICU入室时平均IL-6血清浓度组间无差异(214.4 ± 328.8 vs. 155.8 ± 159.6 pg/ml,p = 0.511)。吸附器前后IL-2、IL-6、IL-8、IL-10、硫酸乙酰肝素和肌红蛋白水平下降,但ICU第1、2天IL-6组间无差异。治疗组ICU第2天心脏指数升高(3.2 ± 0.7 vs. 2.47 ± 0.47 l/min/m2,p = 0.012),液体和纤维蛋白原需求降低,但肾替代治疗需求、机械通气时间、感染并发症、谵妄评分、ICU和住院时间及死亡率均无差异。
要点
- 主要终点ICU入室时IL-6组间无差异:血液吸附组214.4 ± 328.8 vs. 标准治疗组155.8 ± 159.6 pg/ml,p = 0.511。
- 治疗组ICU第2天心脏指数升高(3.2 ± 0.7 vs. 2.47 ± 0.47 l/min/m2,p = 0.012),液体和纤维蛋白原需求降低。
- 肾替代治疗需求无差异,但治疗组肾替代治疗持续时间缩短。
- 机械通气时间、感染并发症、谵妄评分、ICU和住院时间及死亡率组间无差异。
- 吸附器前后IL-2、IL-6、IL-8、IL-10、硫酸乙酰肝素和肌红蛋白水平下降,但术后其他细胞因子浓度组间无显著差异。
适用人群与场景
- >65岁接受择期体外循环心脏手术的患者。
处置流程与药物剂量
- 术中体外循环期间使用血液吸附(CytoSorb)或标准治疗(不进行血液吸附)。
研究设计与关键结果
- 前瞻性随机对照试验,38例患者随机分为血液吸附组(n=19)或标准治疗组(n=19)。
- 主要终点ICU入室时平均IL-6血清浓度组间无差异:血液吸附组214.4 ± 328.8 vs. 标准治疗组155.8 ± 159.6 pg/ml,p = 0.511。
- 术中吸附器前后IL-2、IL-6、IL-8、IL-10、硫酸乙酰肝素和肌红蛋白水平下降。
- ICU第1天和第2天IL-6水平组间无差异;序贯器官衰竭评估评分、乳酸、C反应蛋白和降钙素原无统计学显著差异。
- 治疗组ICU第2天心脏指数升高(3.2 ± 0.7 vs. 2.47 ± 0.47 l/min/m2,p = 0.012),液体需求降低,纤维蛋白原需求降低。
- 肾替代治疗需求无差异,但治疗组肾替代治疗持续时间缩短;机械通气时间、呼吸参数、感染并发症、谵妄评分、ICU和住院时间及死亡率组间无差异。
证据类型、等级与局限
- 证据类型:前瞻性随机对照试验(RECCAS)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论:血液吸附未降低ICU入室时或之后的IL-6水平,尽管治疗组术中细胞因子负荷降低;其他细胞因子术后过程、器官功能障碍、ICU和住院时间及死亡率组间无显著差异。
指南或共识出处
- 试验注册:DRKS00007928;研究方案发表于Trials 2016;17:137。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cardiopulmonary bypass (CPB) triggers marked cytokine release often followed by a systemic inflammatory response syndrome, associated with adverse postoperative outcomes. This trial investigates the intraoperative use of haemoadsorption (HA) during cardiac surgery with CPB to assess its impact on postoperative systemic inflammatory response.
METHODS: In this prospective randomised controlled trial (ethics approval no. 5094-14DRKS00007928), patients (> 65 years) undergoing elective on-pump cardiac surgery were randomised to intraoperative HA (CytoSorb) during CPB or standard care without HA. Primary outcome was the difference in mean interleukin (IL)-6 serum concentrations between groups on intensive care unit (ICU) admission. The secondary outcomes included various clinical and biochemical endpoints. Statistical methods included paired and unpaired t-tests, Wilcoxon, Mann-Whitney U-tests, and chi-square tests.
RESULTS: Thirty-eight patients were allocated to receive either intraoperative HA (n = 19) or standard care (n = 19). The primary outcome, IL-6 levels on ICU admission, did not differ between the study group and controls (214.4 ± 328.8 vs. 155.8 ± 159.6 pg/ml, p = 0.511). During surgery pre- versus post-adsorber IL-2, IL-6, IL-8, IL-10, heparan sulfate and myoglobin post- levels were reduced. Furthermore, IL-6 levels did not differ between the study groups on day 1 and 2 in the ICU. While sequential organ failure assessment scores, lactate levels, and C-reactive protein and procalcitonin (PCT) showed no statistically significant differences. Regarding haemodynamic stability in the treatment group the cardiac index (3.2 ± 0.7 vs. 2.47 ± 0.47 l/min/m2, p = 0.012) on ICU day 2 increased, and lower fluid requirements as well as decreased fibrinogen requirement were observed. Need for renal replacement therapy did not differ though a shorter duration was observed in the treatment group. Time on ventilator, respiratory parameters, infectious complications, delirium scores, ICU and hospital lengths of stay, and mortality did not differ between groups.
CONCLUSION: HA did not reduce the IL-6 level on ICU admission or afterwards. Even though HA reduced cytokine load during cardiac surgery in the treatment group. There were no significant differences between groups in the postoperative course of other cytokine concentrations, organ dysfunction, ICU and hospital lengths of stay and mortality rates. Trial registration prospectively DRKS00007928 and published under: Baumann A, Buchwald D, Annecke T, Hellmich M, Zahn PK, Hohn A. RECCAS - REmoval of Cytokines during Cardiac Surgery: study protocol for a randomised controlled trial.
TRIALS: 2016;17: 137.
参考来源
- Hohn A, Malewicz-Oeck NM, Buchwald D, et al. REmoval of cytokines during CArdiac surgery (RECCAS): a randomised controlled trial. Crit Care. 2024. PMID: 39668341. doi:10.1186/s13054-024-05175-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。